Effect of bestatin on leukemic cells in acute leukemia and myelodysplastic syndromes

Biotherapy

Volumn 17, Issue 2, 2003, Pages 161-166

  Yamada, Shu ^c   Okamoto, Takahiro ^b   Okada, Masaya ^c   Wakae, Takeshi ^c   Takatsuka, Hiroyuki ^c   Kakishita, Eizo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Takarazuka Municipal Hospital   (Japan)

^c NONE

Author keywords

Acute myelogenous leukemia; Annexin V; Apoptosis; Bestatin; Caspase 3

Indexed keywords

BESTATIN; BESTATIN DERIVATIVE; BESTATIN METHYL ESTER; CASPASE 3; DNA FRAGMENT; LIPOCORTIN 5; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME;

EID: 0037368335     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Abe, F., Shibuya, K., Uchida, M. et al.: Effect of bestatin on syngeneic tumors in mice. Gann 75: 89-94, 1984.
2. Yamagishi, H., Sugiyama, K. and Ichihara, K.: Effect of ubenimex on the immune system of patients with hematological malignancies. Biomed. Pharmacother. 45: 105-112, 1991.
3. Yamagishi, H., Naito, K., Ueda, Y. et al.: Bestatin administration and the change in cellular immunity. Biomed. Pharmacother. 45: 117-120, 1991.
4. Murata, M., Kubota, Y., Tanaka, T. et al.: Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells. Leukemia 8: 2188-2193, 1994.
5. Ino, K., Goto, S., Kosaki, A. et al.: Growth inhibitory effect of bestatin on choriocarcinoma cell lines in vitro. Biotherapy 3: 351-357, 1991.
6. Ino, K., Goto, S, Okamoto, T. et al.: Expression of aminopeptidase N in human choriocarcinoma cells and cell growth suppression by the inhibition of aminopeptidase N activity. Jpn. J. Cancer Res. 85: 927-933, 1994.
7. Saiki, I., Fujii, H., Yoneda, J. et al.: Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer 54: 137-143, 1993.
8. Sekine, K., Fujii, H. and Abe, F.: Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 13: 729-734, 1999.
9. Ezawa, K., Minato, K. and Dobashi, K.: Induction of apoptosis by ubenimex (bestatin) in human non-small-cell lung cancer cell lines. Biomed. Pharmacother. 50: 283-289, 1996.
10. Terui, Y., Tomizuka, H., Mishima, Y. et al.: NH2-terminal pentapeptidase of endothelial interleukin 8 is responsible for the induction of apoptosis in leukemic cells and has an anti-tumor effect in vivo. Cancer Res. 59: 5651-5655, 1999.
11. Kobayashi, T., Miyawaki, M., Tanimoto, M. et al.: Randomized trial between behenyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. J. Clin. Oncol. 14: 204-213, 1996.
12. Koyama, M.: Pharmacokinetics and biotransformation of bestatin. In Recent result of bestatin 1986 (edited by Umezawa, H.), Jpn. Antibiotics Res. Assoc. Tokyo, 1987, pp. 44-50.